$7.67 Million in Sales Expected for UROGEN PHARMA (URGN) This Quarter
Analysts expect UROGEN PHARMA (NASDAQ:URGN) to report sales of $7.67 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for UROGEN PHARMA’s earnings, with estimates ranging from $7.50 million to $8.00 million. The company is expected to report its next earnings report on Monday, November 13th.
According to Zacks, analysts expect that UROGEN PHARMA will report full-year sales of $7.67 million for the current year, with estimates ranging from $7.50 million to $8.00 million. For the next financial year, analysts expect that the firm will report sales of $0.00 per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow UROGEN PHARMA.
Several research firms have recently issued reports on URGN. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of UROGEN PHARMA and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research lowered shares of UROGEN PHARMA from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $26.00.
UROGEN PHARMA (NASDAQ:URGN) opened at 30.88 on Thursday. UROGEN PHARMA has a one year low of $13.01 and a one year high of $33.77. The company’s market capitalization is $401.75 million. The stock’s 50 day moving average is $26.18 and its 200 day moving average is $20.40.
Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Spark Investment Management LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $856,000. Menora Mivtachim Holdings LTD. bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $2,331,000. LLBH Private Wealth Management LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $695,000. Alps Advisors Inc. bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $195,000. Finally, Jennison Associates LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $3,168,000. 36.06% of the stock is currently owned by institutional investors.
UROGEN PHARMA Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.